Immunohistochemistry revealed that 50% (25/50) of CRC patients exhibited high JAML expression, primarily localized in the cytoplasm and membranes of cancer cells, with minimal expression in stromal immune cells and negligible levels in adjacent normal tissues. The gene discussed is JAML; the disease is cancer.